Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 4/20 | 0.42 |
| ▸ | PLAU | P00749 | 3/20 | 0.42 |
| ▸ | ELANE | P08246 | 3/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28492827 | 0.78 | KMT2A (0.51) | NOTUMKMT2ASMN1; SMN2RAB9AF2 | |
| SCHEMBL21821206 | 0.75 | PLAU (0.54) | KMT2ASMN1; SMN2RAB9AF2PLAU | |
| Biphenyl SCHEMBL2202263 | 0.74 | NOTUM (0.44) | NOTUMKMT2ASMN1; SMN2RAB9AHPGD | |
| SCHEMBL21816275 | 0.73 | F2 (0.46) | KMT2ASMN1; SMN2RAB9AF2PLAU | |
| SCHEMBL1502065 | 0.73 | KMT2A (0.50) | NOTUMKMT2ASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL3079013 | 0.73 | TP53 (0.54) | KMT2ASMN1; SMN2RAB9AGAAALDH1A1 | |
| SCHEMBL4502875 | 0.72 | — | — | |
| Bicarbonate SCHEMBL15511343 | 0.72 | F2 (0.45) | KMT2ASMN1; SMN2RAB9AF2PLAU | |
| SCHEMBL5278040 | 0.69 | KCNJ1 (0.36) | KMT2ARAB9AHPGDALDH1A1HMOX1 | |
| SCHEMBL1608161 | 0.69 | ALDH1A1 (0.61) | KMT2ASMN1; SMN2F2PLAUELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102341378-A | PROCESS FOR PREPARATION OF 1-ALKYL-5-BENZOYL-1H-TETRAZOLE DERIVATIVES | NIPPON SODA CO | 2012-02-01 | — | — | CN | claimed |
| US-5767270-A | PROTECTING EXOCYCLIC AMINO GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1998-06-16 | — | — | US | claimed |
| US-8252919-B2 | 2′-hydroxy-protected ribonucleoside derivative and production method thereof | KANEKA CORPORATION (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20110009609-A1 | 2'-HYDROXY-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND PRODUCTION METHOD THEREOF | KANEKA CORPORATION (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2258709-A1 | 2'-HYDROXYL-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND MANUFACTURING METHOD OF SAME | Kaneka Corporation (JP) | 2010-12-08 | — | — | EP | disclosed |
| US-6861514-B2 | Nucleosidic and non-nucleosidic folate conjugates | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20020049163-A1 | Nucleosidic and non-nucleosidic folate conjugates | ISIS PHARMACEUTICALS, INC. | 2002-04-25 | — | — | US | disclosed |
| US-6335434-B1 | FOR INCREASED MEMBRANE PERMEABILITY OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC., | 2002-01-01 | — | — | US | disclosed |
| WO-1999066063-A9 | NUCLEOSIDIC AND NON-NUCLEOSIDIC FOLATE CONJUGATES | ISIS PHARMACEUTICALS INC (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999066063-A2 | NUCLEOSIDIC AND NON-NUCLEOSIDIC FOLATE CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-23 | — | — | WO | disclosed |
| US-5767270-A | PROTECTING EXOCYCLIC AMINO GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1998-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049163-A1 | Nucleosidic and non-nucleosidic folate conjugates | MTHFD1, DHFR, FOLR1 | NOTUM 1626/4885KMT2A 2141/4885SMN1; SMN2 2160/4885 |
| US-20110009609-A1 | 2'-HYDROXY-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND PRODUCTION METHOD THEREOF | RNASEL, RNASEH1, NUDT1 | NOTUM 2260/4885KMT2A 721/4885SMN1; SMN2 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.